Readmissions, Postdischarge Mortality, and Sustained Recovery Among Patients Admitted to Hospital With Coronavirus Disease 2019 (COVID-19)
Clinical Infectious Diseases · 2023
DOI: 10.1093/cid/ciac639 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Infectious Diseases, 2023. Verfasst von Kasper S Moestrup und 10 weiteren Autor:innen. Beteiligte Einrichtung: Rigshospitalet, Centre of Excellence for Health, Immunity, and Infections (CHIP ), Copenhagen, Denmark. Hauptthemen laut MEDLINE: COVID-19. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Danish Ministry of Higher Education and Science, Danish National Research Foundation.
Abstract (Originalsprache)
Background
Many interventional in-patient coronavirus disease 2019 (COVID-19) trials assess primary outcomes through day 28 post-randomization. Since a proportion of patients experience protracted disease or relapse, such follow-up period may not fully capture the course of the disease, even when randomization occurs a few days after hospitalization.
Methods
Among adults hospitalized with COVID-19 in eastern Denmark from 18 March 2020–12 January 2021 we assessed all-cause mortality, recovery, and sustained recovery 90 days after admission, and readmission and all-cause mortality 90 days after discharge. Recovery was defined as hospital discharge and sustained recovery as recovery and alive without readmissions for 14 consecutive days.
Results
Among 3386 patients included in the study, 2796 (82.6%) reached recovery and 2600 (77.0%) achieved sustained recovery. Of those discharged from hospital, 556 (19.9%) were readmitted and 289 (10.3%) died. Overall, the median time to recovery was 6 days (interquartile range [IQR]: 3–10), and 19 days (IQR: 11–33) among patients in intensive care in the first 2 days of admission.
Conclusions
Postdischarge readmission and mortality rates were substantial. Therefore, sustained recovery should be favored to recovery outcomes in clinical COVID-19 trials. A 28-day follow-up period may be too short for the critically ill.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Rigshospitalet, Centre of Excellence for Health, Immunity, and Infections (CHIP ), Copenhagen, Denmark.
- Department of Infectious Diseases, Nordsjællands Hospital, Hillerød, Denmark.
- Department of Respiratory Diseases, Herlev and Gentofte Hospital, Hellerup, Denmark.
- Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
- Department of Infectious Diseases, Zealand University Hospital, Roskilde, Denmark.
- Department of Immunology, Rigshospitalet, Copenhagen, Denmark.
ORCID-Profile: Kasper S Moestrup
Förderung
- Danish Ministry of Higher Education and Science
- Danish National Research Foundation
Zitieren
APA
Moestrup, K. S., Reekie, J., Zucco, A. G., Jensen, T. Ø., Jensen, J. S., Wiese, L., Ostrowski, S. R., Niemann, C. U., MacPherson, C., Lundgren, J., & Helleberg, M. (2023). Readmissions, Postdischarge Mortality, and Sustained Recovery Among Patients Admitted to Hospital With Coronavirus Disease 2019 (COVID-19). Clinical Infectious Diseases. https://doi.org/10.1093/cid/ciac639
Vancouver
Moestrup KS, Reekie J, Zucco AG, Jensen TØ, Jensen JS, Wiese L, et al. Readmissions, Postdischarge Mortality, and Sustained Recovery Among Patients Admitted to Hospital With Coronavirus Disease 2019 (COVID-19). Clinical Infectious Diseases. 2023. doi:10.1093/cid/ciac639
BibTeX
@article{Moestrup2023,
author = {Moestrup, Kasper S and Reekie, Joanne and Zucco, Adrian G and Jensen, Tomas Ø and Jensen, Jens-Ulrik S and Wiese, Lothar and Ostrowski, Sisse R and Niemann, Carsten U and MacPherson, Cameron and Lundgren, Jens and Helleberg, Marie},
title = {Readmissions, Postdischarge Mortality, and Sustained Recovery Among Patients Admitted to Hospital With Coronavirus Disease 2019 (COVID-19)},
journal = {Clinical Infectious Diseases},
year = {2023},
doi = {10.1093/cid/ciac639}
}
EUVIMED